Jefferies Financial Group Reaffirms “Buy” Rating for GSK (LON:GSK)

GSK (LON:GSK)‘s stock had its “buy” rating restated by equities research analysts at Jefferies Financial Group in a report issued on Thursday,London Stock Exchange reports. They presently have a GBX 2,500 target price on the stock. Jefferies Financial Group’s price objective would indicate a potential upside of 30.16% from the company’s current price.

Several other research analysts have also recently issued reports on the stock. Berenberg Bank reiterated a “hold” rating and issued a GBX 2,000 price objective on shares of GSK in a report on Thursday, March 26th. Citigroup decreased their price objective on shares of GSK from GBX 2,250 to GBX 2,100 and set a “neutral” rating for the company in a report on Wednesday, May 6th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a GBX 1,900 price objective on shares of GSK in a report on Wednesday. Finally, Shore Capital Group restated a “buy” rating on shares of GSK in a report on Wednesday, March 25th. Two investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, GSK presently has a consensus rating of “Hold” and an average target price of GBX 2,034.29.

GSK Trading Down 1.0%

GSK stock opened at GBX 1,920.79 on Thursday. The firm has a 50 day simple moving average of GBX 2,004.93 and a 200-day simple moving average of GBX 1,950.73. The company has a debt-to-equity ratio of 106.74, a current ratio of 0.79 and a quick ratio of 0.73. The stock has a market capitalization of £76.68 billion, a PE ratio of 13.52, a price-to-earnings-growth ratio of 1.24 and a beta of 0.30. GSK has a 12-month low of GBX 1,288.61 and a 12-month high of GBX 2,282.

GSK (LON:GSK) last posted its quarterly earnings data on Wednesday, April 29th. The company reported GBX 46.50 earnings per share (EPS) for the quarter. The business had revenue of GBX 762.90 billion during the quarter. GSK had a net margin of 17.78% and a return on equity of 35.78%. As a group, equities research analysts expect that GSK will post 175.980975 EPS for the current fiscal year.

Insider Activity at GSK

In other news, insider Wendy Becker purchased 4,000 shares of GSK stock in a transaction that occurred on Wednesday, April 29th. The stock was acquired at an average price of GBX 1,963 per share, for a total transaction of £78,520. Also, insider Anne Beal purchased 196 shares of GSK stock in a transaction that occurred on Friday, March 20th. The stock was purchased at an average price of GBX 5,179 per share, with a total value of £10,150.84. In the last 90 days, insiders bought 9,619 shares of company stock worth $19,452,794. 0.20% of the stock is owned by corporate insiders.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.